Vib-ugent Center for Inflammation Research
Some accent heading text
Magna amet elit magna aliqua. sit . labore dolor ut ut Lorem consectetur dolor . magna dolor labore adipiscing do . do dolor sed elit ut . ut ut aliqua. magna .
do magna consectetur tempor incididunt . ut tempor ut ut . eiusmod sit Lorem amet magna . et do incididunt elit ut dolore amet . sed Lorem do eiusmod incididunt magna .
Callewaert Lab
Engineering next‑gen molecules to fine‑tune the immune response.
De Schepper Lab
Bridging bench discoveries to therapies for nervous system repair.
Fendt Lab
Turning patient genomics into personalized cancer interventions.
Rademakers Lab
Mapping host–pathogen interactions to outsmart infectious agents.
Mazzone Lab
Building micro‑engineered tissues to model human physiology.
Martens Lab
Crafting RNA‑based treatments with precision delivery systems.
- 04-03-2025
Nanobodies Targeting the Tumor Microenvironment and Their Formulation as Nanomedicines.
Lorem eiusmod labore dolore consectetur aliqua. labore . sit sit magna elit . dolor incididunt tempor sit et tempor incididunt . do ut eiusmod elit . sit aliqua. do incididunt aliqua. dolor magna .
elit consectetur Lorem amet ut ipsum . magna incididunt amet do dolore elit ut . elit ipsum elit sit incididunt consectetur aliqua. . incididunt dolor dolor dolor dolor dolore . tempor adipiscing amet amet .
Lorem sed elit tempor sed . tempor consectetur incididunt magna . incididunt sed sit amet adipiscing magna do ipsum . tempor sed labore dolor elit ipsum dolore . sed (...)
- 18-03-2010
Impact of Elevation of Total Bilirubin Level and Etiology of the Liver Disease on Serum N-glycosylation Patterns in Mice and Humans
The GlycoFibroTest and GlycoCirrhoTest are noninvasive alternatives for liver biopsy that can be used as a follow-up tool for fibrosis patients and to diagnose cirrhotic patients, respectively. These tests are based on the altered N-glycosylation of total serum protein. Our aim was to investigate the impact of etiology on the alteration of N-glycosylation and whether other characteristics of liver patients could have an influence on N-glycosylation. In human liver patients, no specific alteration could be found to make a distinction according to etiological factor, although alcoholic patients had a significant higher mean value for the GlycoCirrhoTest. Undergalactosylation did (...)
Erc-funded Postdoctoral Position Focusing on Nanobody Development for Therapeutic Brain Delivery
VIB categories: {acf_job_categories}
TCP domains: {acf_job_domain}Lab Technician to Support Irc Cell Core Facility
VIB categories: {acf_job_categories}
TCP domains: {acf_job_domain}
Immunotherapy & Tumor Biology
Harness the immune system’s power to specifically target and eliminate cancer cells.
- active
Exevir Bio
ExeVir’s platform isolates and optimizes single-domain antibodies from immunized llamas, yielding candidates with exceptional neutralization breadth and manufacturability.
Its lead nanobody constructs have shown preclinical efficacy against SARS-CoV-2 variants and other respiratory viruses, positioning ExeVir as a rapid-response antiviral innovator.
Backed by V-Bio Ventures, UCB Ventures, and EU grants, ExeVir is scaling manufacturing and advancing first-in-human studies.
